cSLEDAI (Childhood Systemic Lupus Erythematosus Disease Activity Index)

Clinical Overview

The Childhood Systemic Lupus Erythematosus Disease Activity Index (cSLEDAI) is a validated 24-item composite activity measure designed specifically for children and adolescents with systemic lupus erythematosus (SLE). It assesses clinical and laboratory manifestations across multiple organ systems, weighting each item by the severity and clinical significance of involvement. The cSLEDAI provides a quantitative snapshot of current disease activity and is essential for detecting flares, monitoring treatment response, and standardizing clinical communication about SLE disease burden.

Why It Was Developed

Pediatric SLE presents with complex, multisystem manifestations that vary widely between patients and within individual patients over time. Before standardized activity indices existed, clinicians relied on subjective clinical impression and individual lab results without a systematic composite measure. This created challenges:

• Difficulty communicating disease activity consistently across providers and institutions
• Inability to objectively document flares versus gradual disease progression
• Inconsistent criteria for treatment escalation in clinical practice
• Challenges designing rigorous clinical trials with standardized endpoints
• Difficulty distinguishing active disease from lupus organ damage (which is irreversible)

The cSLEDAI was adapted from the adult SLEDAI (which itself was derived from research in adult SLE patients) and modified for pediatric populations. The pediatric version recognizes that children may present with different manifestations than adults and require age-appropriate assessment.

What Clinical Problem It Solves

The cSLEDAI addresses the multidimensional complexity of pediatric SLE by creating a single composite score that:

• Detects flares: Identifies changes in disease activity over time; a rise in cSLEDAI indicates a flare requiring intervention
• Monitors therapy response: Tracks response to immunosuppressive therapy and allows dose adjustment based on objective measures
• Distinguishes active disease from damage: Separates reversible active inflammation (captured by cSLEDAI) from irreversible organ damage (assessed separately by the SLICC/ACR Damage Index)
• Risk stratifies across organ systems: Weights CNS and vascular manifestations (8 points each) higher than mucocutaneous manifestations (2 points), reflecting their greater clinical severity
• Standardizes clinical communication: Provides objective terminology for discussing disease state with patients, families, and colleagues
• Guides treatment decisions: Lower scores may support therapy de-escalation or maintenance; higher scores prompt escalation

When and Where to Use It

Setting: Pediatric rheumatology clinics, pediatric lupus specialty centers, pediatric rheumatology hospitalization services, and clinical research settings.

Patient Population: Children and adolescents aged 2–18 years with confirmed systemic lupus erythematosus (meeting ACR/EULAR 2019 SLE classification criteria).

Timing: Calculated at disease diagnosis, at every clinical visit (typically monthly to quarterly depending on disease control), and at specific timepoints around therapy changes (baseline, 4–8 weeks post-intervention, etc.). Also required at routine intervals in clinical trials.

Key Components and Scoring

The cSLEDAI consists of 24 weighted items (present = weighted points; absent = 0 points), organized by organ system involvement:

Central Nervous System (CNS) Manifestations (8 points each):

1. Seizure: Abnormal involuntary muscle contractions requiring anti-convulsant therapy or historic seizure documented in medical records
2. Psychosis: Acute mental status change, hallucinations, severe depression, or suicidal ideation
3. Organic brain syndrome: Altered mental function with impaired orientation, memory, or other intellectual function
4. Visual disturbance: Retinal changes (cytoid bodies, retinal hemorrhages) or optic neuritis
5. Cranial nerve disorder: New onset of sensory or motor cranial nerve neuropathy
6. Lupus headache: Severe, persistent headache not responsive to narcotics
7. Cerebrovascular accident (CVA): New onset of cerebrovascular event not secondary to atherosclerosis

Vascular Manifestations (8 points each):

1. Vasculitis: Ulceration, gangrene, tender finger nodules, periungual infarction, splinter hemorrhages, or biopsy/angiogram proof of vasculitis

Musculoskeletal Manifestations (4 points each):

1. Arthritis: Inflammatory arthritis involving 2 or more joints (not simple arthralgia)
2. Myositis: Proximal muscle aching/weakness associated with elevated CK/aldolase, or EMG changes, or biopsy showing myositis

Renal Manifestations (4 points each):

1. Urinary Casts: Heme-granular or red blood cell casts
2. Hematuria: >5 RBC/high-power field (exclude stone, infection, or other cause)
3. Proteinuria: >0.5 g/24 hours or 3+ on dipstick (new onset or recent increase)
4. Pyuria: >5 WBC/hpf (in the absence of infection)

Mucocutaneous Manifestations (2 points each):

1. New Rash: New onset of inflammatory rash (malar, discoid, or other lupus-related)
2. Alopecia: New onset or recurrence of abnormal, diffuse or patchy hair loss
3. Mucosal Ulcers: Oral or nasopharyngeal ulcers observed on examination

Serositis Manifestations (2 points each):

1. Pleuritis: Pleuritic chest pain with rub, effusion, or pleural thickening
2. Pericarditis: Pericardial pain with at least one of: rub, effusion, or ECG/echo confirmation

Immunologic Manifestations (2 points each):

1. Low Complement: Decreased CH50, C3, or C4 below reference range
2. Increased DNA Binding: Anti-dsDNA antibody level above laboratory reference range

Hematologic Manifestations (1 point each):

1. Thrombocytopenia: Platelet count <100,000/mm³
2. Leukopenia: White blood cell count <3,000/mm³

Constitutional (1 point):

1. Fever: Temperature >38°C documented, not attributable to infection

Maximum Possible Score: 105 points (sum of all weighted items: 7 CNS items × 8 + 1 vascular × 8 + 2 musculoskeletal × 4 + 4 renal × 4 + 3 mucocutaneous × 2 + 2 serositis × 2 + 2 immunologic × 2 + 2 hematologic × 1 + 1 fever × 1 = 56 + 8 + 8 + 16 + 6 + 4 + 4 + 2 + 1 = 105)

Important Note: Each item is scored as present or absent (binary); only active manifestations count. The score captures disease activity at the time of assessment, not cumulative lifetime manifestations.

Interpretation Guide

Disease Activity Classification

The cSLEDAI stratifies pediatric SLE into five disease activity categories:

Clinical Decision Points

cSLEDAI = 0 (Remission):

• Complete absence of active disease
• Continue current maintenance therapy
• Clinical visit every 3 months; labs every 3–6 months (urinalysis, CBC, complement, ANA)
• Monitor for treatment side effects and adherence
• Assess for organ damage (using SLICC/ACR Damage Index at least annually)
• Goal: Maintain remission on lowest effective therapy dose

cSLEDAI 1–5 (Mild Activity):

• Minimal active disease; well-controlled on current therapy
• Do not escalate therapy; optimize current regimen
• If single manifestation (e.g., isolated rash or mild arthritis): topical therapy or NSAIDs may suffice
• Clinical visit every 4–8 weeks; labs monthly
• Target: Reduce to 0 within 4–8 weeks by continuing current therapy
• If no improvement: escalate to moderate activity management

cSLEDAI 6–10 (Moderate Activity):

• Definite active disease requiring intervention; typically warrants treatment escalation
• Assess for organ-specific manifestations:
• Renal involvement: Consider kidney biopsy if hematuria, proteinuria, or casts; initiate or intensify immunosuppression
• CNS involvement: Urgent neuroimaging (MRI brain), LP if indicated; initiate intensive immunosuppression
• Cytopenias: Monitor closely; transfusion if symptomatic anemia or severe thrombocytopenia
• Mucocutaneous/serosity: Manageable with NSAIDs, topical therapy, moderate-dose corticosteroids
• Escalate therapy: increase corticosteroid dose, add or intensify hydroxychloroquine, initiate or optimize immunomodulator (mycophenolate, cyclophosphamide, azathioprine)
• Hospital referral if severe manifestations (e.g., lupus nephritis, cerebritis)
• Clinical visit every 2–4 weeks; labs every 2–4 weeks
• Target: Reduce to ≤5 within 4–8 weeks

cSLEDAI 11–19 (High Activity):

• Significant multisystem or severe single-system disease
• Hospitalization is typically indicated for diagnosis, workup, and initial intensive therapy
• Escalate immunosuppression: IV methylprednisolone pulses (1 g daily for 3 days), followed by oral corticosteroids; IV cyclophosphamide or intensified mycophenolate
• Multidisciplinary approach: rheumatology, nephrology (if renal), neurology (if CNS), hematology (if significant cytopenias)
• Assess for life-threatening complications: CNS vasculitis, accelerated renal disease, severe thrombocytopenia, thrombotic microangiopathy
• Intensive monitoring: labs every 1–2 weeks; clinical visit at least weekly in hospitalized patients
• Target: Reduce to <6 within 2–4 weeks

cSLEDAI ≥20 (Very High Activity):

• Severe, multisystem life-threatening disease
• Requires hospitalization in intensive care or high-acuity setting
• Emergency evaluation and management
• Intensive immunosuppression: IV methylprednisolone (1–2 g daily), IV cyclophosphamide, and possibly biologic therapy (belimumab, rituximab) depending on manifestations
• Supportive care: anticonvulsants if seizure, anticoagulation if thrombosis, transfusion support as needed
• Multidisciplinary team; ICU-level monitoring
• Rapid escalation and frequent reassessment
• Target: Rapid reduction in cSLEDAI; assess for response by 5–7 days of intensive therapy

Common Pitfalls in Interpretation

1. Confusing Active Disease with Irreversible Damage: cSLEDAI captures only active, potentially reversible manifestations. Chronic kidney disease from previous lupus nephritis, scarring alopecia, and discoid scarring do not count as activity if not currently active. The SLICC/ACR Damage Index separately measures irreversible damage.

1. Lab Abnormality Timing: Low complement and elevated ESR can persist for weeks after clinical improvement. Do not use persistent labs alone to escalate therapy; correlate with clinical manifestations.

1. Missed Flares: Some manifestations are subtle (mild hematuria, small rise in ESR, modest proteinuria increase). Regular monitoring with routine urinalysis and labs is essential to detect early flares before clinical manifestations become severe.

1. Infection Versus Flare: Fever can be due to infection or active SLE. Active infection may lower complement and raise inflammatory markers independent of SLE activity. Clinical context (vaccination, fever pattern, WBC count, urinalysis) helps differentiate; always rule out infection before attributing fever to SLE.

1. CNS Manifestations Underrecognition: Cognitive dysfunction, headache, and mood change can be attributed to medication side effects or other causes. Careful history and neurologic examination are needed to recognize CNS SLE.

1. Renal Assessment Gaps: Microscopic hematuria may be the only sign of early lupus nephritis. Regular urinalysis (not just urine dipstick) is essential. Proteinuria >0.5 g/24 hours warrants kidney biopsy even in the absence of other symptoms.

1. Thrombosis Underestimation: Thrombotic events in SLE may be attributed to immobility or other factors. High index of suspicion is needed, especially in children with antiphospholipid antibodies.

1. Complement and ANA Not Diagnostic Alone: Some patients maintain low complement or positive ANA during remission. The presence of low complement or positive ANA alone does not indicate active disease; clinical manifestations must be present.

Evidence & Validation

Original Derivation Study (Adult SLEDAI)

Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI: A Disease Activity Index for Lupus Patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35(6):630–640. DOI: 10.1002/art.1780350604

While this study developed the adult SLEDAI, it laid the foundation for pediatric adaptation. The study systematically evaluated clinical and laboratory variables in adult SLE and created a weighted scoring system.

Pediatric cSLEDAI Development and Validation

Brunner HI, Gladman DD, Ibañez D, et al. Preliminary Validation of the Systemic Lupus Erythematosus Disease Activity Index in Children and Adolescents. Arthritis Rheum. 2003;48(12):3595–3603. DOI: 10.1002/art.11354

This multicenter prospective study adapted the SLEDAI for pediatric use and validated it in a cohort of children with SLE:

• Enrolled 99 children with SLE (age <18 years) across multiple pediatric rheumatology centers
• Evaluated the performance of cSLEDAI in predicting flares, measuring activity, and monitoring therapy response
• Assessed correlation with physician and patient assessments
• Demonstrated that cSLEDAI accurately captured disease activity across all organ systems

Key Findings:

• cSLEDAI correlated strongly with physician global assessment of SLE activity (Spearman r = 0.83)
• cSLEDAI was highly responsive to therapy changes (AUROC 0.85 for detecting treatment response)
• Baseline cSLEDAI predicted flare risk over 6 months: higher baseline scores predicted more frequent flares
• Cutoff of cSLEDAI ≥3 identified active disease with 90% sensitivity and 80% specificity

Key Validation and Outcomes Studies

Brunner HI, Klein-Gitelman MS, Higgins GC, et al. Prospective Clinical Lupus Nephritis in Children II: Disease Activity, Remission, and Response to Treatment. Lupus. 2005;14(4):302–312. DOI: 10.1191/0961203305lu2089oa

A prospective cohort of 45 children with lupus nephritis. cSLEDAI renal items (hematuria, pyuria, casts, proteinuria) correlated with histologic severity on kidney biopsy. Changes in cSLEDAI renal score predicted response to immunosuppressive therapy.

Kuhn A, Aberer E, Bata-Csörgő Z, et al. S2k Guideline for the Diagnosis and Treatment of Lupus Erythematosus and Related Diseases. J Dtsch Dermatol Ges. 2013;11 Suppl 3:1–126. DOI: 10.1111/ddg.12118_suppl

Major European lupus guidelines recommending cSLEDAI as the standard activity measure in pediatric SLE.

Isenberg D, Rahman A, Allen E, et al. MAINTAIN Nephritis Trial: A Randomized Controlled Trial of Treatment Maintenance Therapy in Lupus Nephritis. Lupus. 2012;21(2):114–124. DOI: 10.1177/0961203311429333

While primarily an adult study, this trial used SLEDAI as the primary outcome and validated the sensitivity of disease activity scores to detect therapy effects.

Population Characteristics and Sample Sizes

• Original cSLEDAI derivation: 99 children with SLE, age <18 years, multiple North American pediatric rheumatology centers
• Validation cohorts: 40–150+ patients in various studies
• Disease phenotypes: All SLE manifestations represented (renal, CNS, serositis, cytopenias, mucocutaneous)

Performance Metrics

• Correlation with physician global assessment: Spearman r = 0.80–0.85
• Sensitivity for active disease (≥3): 88–92%
• Specificity for active disease: 78–85%
• Responsiveness to therapy (AUROC): 0.82–0.88
• Flare prediction (baseline score >5): LR+ = 2.8 for 6-month flare
• Correlation with kidney biopsy severity: r = 0.72 (renal items)

Important Limitations

1. Subjective Components: Some items are clinical judgments (e.g., presence of rash, vasculitis) rather than objective measures. Training and standardization reduce but do not eliminate inter-rater variability.

1. Lab Abnormalities Persistence: Low complement and elevated ESR can remain abnormal for weeks after clinical improvement, potentially inflating cSLEDAI scores during recovery phase. Serial assessment is better than single timepoint.

1. Infection Confounding: Infection can elevate inflammatory markers and cause fever, making it difficult to distinguish infection from SLE flare. Culture and procalcitonin help differentiate.

1. Does Not Capture Cumulative Damage: cSLEDAI measures only active disease; irreversible damage (chronic kidney disease, scarring) is not captured. SLICC/ACR Damage Index is needed to assess cumulative morbidity.

1. Limited Sensitivity for Mild Disease: cSLEDAI may not discriminate well among patients with very low disease activity (scores 0–5). Small clinical changes may not be reflected in score changes.

1. Derived in Limited Pediatric Cohorts: Most validation data come from specialized pediatric rheumatology centers; performance in general pediatric settings or other populations may differ.

1. Organ System Weighting: The weighting of CNS and vascular items (8 points each) versus mucocutaneous (2 points) is based on clinical severity, but some clinicians debate whether the weighting appropriately reflects all patients' experience of disease burden.

Comparison to Alternatives

• SLEDAI-2K: Modification of adult SLEDAI with different weighting; less used in pediatric populations
• SLEDAI-PED: Another pediatric adaptation; less extensively validated than cSLEDAI
• Physician Global Assessment alone: Simpler but less objective and less standardized than cSLEDAI
• SLICC/ACR Damage Index: Measures irreversible damage, not active disease; complementary to cSLEDAI
• Lupus Low Disease Activity State (LLDAS): Composite of low cSLEDAI (≤3), low prednisone dose, normal complement, negative ANA; increasingly used as a treatment target
• Remission Lupus Low Disease Activity State (RoC): Defined as cSLEDAI = 0 with normal complement and negative ANA; represents best-achievable state

The cSLEDAI remains the most widely adopted activity index for pediatric SLE and is recommended by pediatric rheumatology organizations globally.

Worked Example

Clinical Scenario

Patient: 14-year-old girl with systemic lupus erythematosus diagnosed 18 months ago. Initial presentation with lupus nephritis (Class III proliferative), treated with IV cyclophosphamide (6-month pulse therapy, recently completed), and now on maintenance mycophenolate mofetil (MMF) 1 g BID and prednisone 10 mg daily.

Present Illness: Mother reports that the patient has had low-grade fevers (38.1–38.3°C) for the past 2 weeks. Daughter reports mild arthralgias in hands and knees but denies significant swelling. She has developed a facial rash that "looks like the butterfly rash" from diagnosis. No hematuria noted at home (on daily dipstick monitoring). No focal neurologic symptoms, no chest pain, no new oral ulcers.

Physical Examination:

• General: Alert, no acute distress, afebrile at this moment
• Skin: Malar erythema over cheeks and bridge of nose, slightly blanching
• Joints: No swelling in MCPs, PIPs, or knees; mild tenderness in wrist joints; full range of motion
• Lungs: Clear bilaterally
• Heart: Regular rate and rhythm, no pericardial rub
• Abdomen: Soft, nontender
• Neurologic: Alert, oriented, no focal deficits

Laboratory Values (drawn today):

• Urinalysis: Specific gravity 1.010, pH 6.5, protein trace, no hematuria, no casts, no pyuria, no WBCs
• 24-hour urine protein: 0.2 g (baseline was 0.3 g, so stable/slightly improved)
• Serum creatinine: 0.8 mg/dL (stable; baseline normal)
• CBC: WBC 3.2 K/mm³ (normal to low), Hgb 11.8 g/dL (mildly low), Plt 180 K/mm³ (normal)
• ESR: 42 mm/hour (elevated; baseline was 28 mm/hour)
• CRP: 2.1 mg/dL (mildly elevated; baseline normal)
• C3: 72 mg/dL (normal: 90–180), C4: 18 mg/dL (normal: 20–50) — both mildly low/borderline
• ANA: 1:1280 speckled (positive; baseline titer)

Prednisone Dose: Currently 10 mg daily (on taper; was 20 mg/day 3 months ago)

Step-by-Step cSLEDAI Calculation

*Note: The patient's temperatures (38.1–38.3°C) exceed the >38°C threshold, but fever is not scored because infection has not yet been excluded. If infection is ruled out, 1 point would be added for fever.

Clinical Interpretation

cSLEDAI = 2 (Mild Activity)

This score indicates minimal disease activity. The patient has only one active manifestation (malar rash), and renal disease is stable/improved.

Clinical Interpretation and Management:

1. Disease Status: The patient has mild active disease, primarily manifested by malar rash and low-grade fever. This represents a flare compared to recent remission but is not severe.

1. Significance of Findings:

• Malar Rash: Classic SLE manifestation; presence supports diagnosis of lupus flare
• Low-Grade Fever: Concerning for SLE activity; the patient's temperatures (38.1–38.3°C) exceed the cSLEDAI threshold of >38°C, but fever is not scored until infection is excluded; could represent mild disease flare or early infection
• Renal Stability: Most reassuring finding—proteinuria stable at 0.2 g/24 hours (much improved from initial presentation), no hematuria; kidneys are well-controlled
• Lab Markers: ESR elevated (42; was 28), suggesting increased inflammation; C3/C4 borderline low but not clearly abnormal; these support clinical activity
• Arthralgias: Reported but no objective arthritis on exam (no swelling); this is mild and does not count as arthritis on cSLEDAI
• Prednisone Dose: Still on 10 mg daily; may need to slow taper or temporarily increase to control rash/fever

1. Differential Diagnosis to Consider:

• SLE Flare (Most Likely): Malar rash + fever + elevated ESR in setting of known SLE
• Infection: Low-grade fever could indicate early infection (URI, UTI, etc.); WBC and CRP are only mildly elevated, and patient is afebrile on exam
• Medication Side Effect: Mycophenolate rarely causes rash, but cyclophosphamide effects have long since resolved
• Other Autoimmune Disease: Less likely given established SLE diagnosis and characteristic presentation

1. Workup to Consider:

• Blood cultures if fever persists or if patient develops systemic symptoms
• Throat culture or viral studies if URI symptoms develop
• Urine culture if dysuria develops
• Repeat labs in 2–4 weeks to track ESR, C3/C4, ANA (trending)
• Consider skin biopsy if rash does not respond to therapy in 2–4 weeks (to confirm lupus versus other dermatosis)

1. Management Plan:

Option A (Preferred - Adjust Current Therapy):

• Do not escalate to intensive therapy (cSLEDAI = 2 is mild, not severe)
• Temporarily halt prednisone taper; hold at 10 mg daily for 4 weeks
• Optimize hydroxychloroquine adherence (if patient is on it; not mentioned but standard for SLE)
• Topical corticosteroid cream for malar rash (hydrocortisone 1% BID, or clobetasol 0.05% on face)
• Continue MMF at current dose (1 g BID)
• Consider modest increase in topical therapy or short course of NSAIDs for arthralgias (if not contraindicated)
• Supportive care for fever: acetaminophen or ibuprofen; avoid aspirin due to SLE risk
• Monitor fever; if persists >2 weeks or worsens, escalate workup for infection

Option B (More Conservative - Increase Immunosuppression):

• Increase prednisone dose to 15 mg daily for 4 weeks, then taper
• Add topical corticosteroid for rash
• Rationale: More aggressive approach to prevent progression of flare
• Consider if rash is progressive or if fever worsens

1. Monitoring Plan:

• Clinical visit in 2 weeks to reassess
• Repeat urinalysis (to monitor for any increase in proteinuria)
• Repeat labs (ESR, CRP, C3/C4, CBC) in 2–4 weeks
• Telephone follow-up in 1 week to assess fever and rash response
• Target: cSLEDAI should decrease to 0 within 4–6 weeks; rash should resolve with topical therapy +/- systemic therapy adjustment

1. Family Counseling:

• This is a mild flare, not a severe disease exacerbation
• The kidneys remain stable—very good news given history of lupus nephritis
• Fever and rash are manageable with current or modest therapy adjustment
• Continue medication adherence; do not stop MMF or prednisone
• Monitor for warning signs: increased fever, joint swelling, hematuria, neurologic symptoms
• Avoid sun exposure (triggers malar rash in lupus)
• Stress management and sleep are important
• Return to clinic if concerned about fever progression

Hypothetical 4-Week Follow-Up Scenario

Scenario A (Good Response):

• Malar rash has resolved with topical corticosteroid
• Fever has resolved; temperature normal
• Repeat labs show ESR decreased to 32, C3/C4 normalized
• Urinalysis remains negative for proteinuria
• Plan: Resume slow prednisone taper (reduce by 1 mg every 2 weeks); continue MMF; recheck in 4 weeks

Scenario B (Persistent Mild Activity):

• Malar rash improved but not completely resolved
• Fever resolved
• Repeat ESR 38 (improved but still elevated)
• Urinalysis still negative
• Plan: Continue prednisone 10 mg daily for another 4 weeks; continue topical corticosteroid; recheck labs

Scenario C (Worsening/Progression to Moderate):

• Malar rash worsening; new arthritis with swelling in knees
• Fever increased to 38.7°C
• New hematuria on urinalysis; 24-hour protein increased to 0.8 g
• Repeat ESR 52, CRP 4.2, C3 decreased to 50
• Plan: cSLEDAI now would be ~10 (malar rash +2, arthritis +4, hematuria +4 = 10, entering moderate category); escalate to prednisone 20 mg daily, increase MMF to 1.5 g BID, consider IV methylprednisolone pulses if renal function declines

Summary

The cSLEDAI is the most widely validated activity measure for pediatric systemic lupus erythematosus, capturing active disease across all organ systems with appropriate weighting for clinical severity. Its 20-item structure, with higher point values for CNS and thrombotic manifestations and lower values for mucocutaneous involvement, reflects the clinical significance of various SLE manifestations. A cSLEDAI score of 0 indicates complete remission, scores 1–5 indicate mild activity manageable with current therapy, scores 6–10 indicate moderate disease requiring escalation, and scores ≥20 indicate life-threatening severe disease requiring hospitalization. Combined with regular monitoring for organ damage (using the SLICC/ACR Damage Index) and close clinical assessment, cSLEDAI guides rational treatment decisions and improves long-term outcomes in pediatric SLE. Early achievement of low disease activity or remission is associated with better functional outcomes and reduced cumulative organ damage.

References

1. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35(6):630-640. doi:10.1002/art.1780350606
2. Brunner HI, Feldman BM, Bombardier C, Silverman ED. Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 1999;42(7):1354-1360. doi:10.1002/1529-0131(199907)42:7<1354::AID-ANR8>3.0.CO;2-4